CAH Stock - Cardinal Health, Inc.
Unlock GoAI Insights for CAH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B |
| Gross Profit | $8.17B | $7.41B | $6.89B | $6.48B | $6.78B |
| Gross Margin | 3.7% | 3.3% | 3.4% | 3.6% | 4.2% |
| Operating Income | $2.27B | $1.24B | $752.00M | $-607,000,000 | $472.00M |
| Net Income | $1.56B | $852.00M | $330.00M | $-938,000,000 | $611.00M |
| Net Margin | 0.7% | 0.4% | 0.2% | -0.5% | 0.4% |
| EPS | $6.48 | $3.48 | $1.26 | $-3.34 | $2.09 |
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $243 |
| June 3rd 2025 | Wells Fargo | Upgrade | Overweight | $179 |
| February 5th 2025 | Jefferies | Upgrade | Buy | $150← $140 |
| January 8th 2025 | TD Cowen | Upgrade | Buy | $144← $130 |
| January 7th 2025 | Evercore ISI | Upgrade | Outperform | $140 |
| January 6th 2025 | BofA Securities | Upgrade | Buy | $145← $132 |
| December 13th 2024 | Wells Fargo | Upgrade | Equal Weight | $127← $101 |
| December 4th 2024 | Mizuho | Resumed | Outperform | $139 |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $125 |
| February 9th 2024 | Argus | Upgrade | Buy | - |
| January 3rd 2024 | Barclays | Initiation | Overweight | $117 |
| December 14th 2023 | Wells Fargo | Initiation | Underweight | $96 |
| July 10th 2023 | Evercore ISI | Downgrade | In-line | $100 |
| March 31st 2023 | Citigroup | Initiation | Neutral | $77 |
| February 3rd 2023 | Robert W. Baird | Upgrade | Outperform | $94← $87 |
Earnings History & Surprises
CAHEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Jan 29, 2026 | $2.31 | — | — | — |
Q4 2025 | Oct 30, 2025 | $2.18 | $2.55 | +17.0% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $2.04 | $2.08 | +2.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $2.17 | $2.35 | +8.3% | ✓ BEAT |
Q1 2025 | Jan 30, 2025 | $1.74 | $1.93 | +10.9% | ✓ BEAT |
Q4 2024 | Nov 1, 2024 | $1.62 | $1.88 | +16.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $1.73 | $1.84 | +6.4% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $1.95 | $2.08 | +6.7% | ✓ BEAT |
Q1 2024 | Feb 1, 2024 | $1.60 | $1.82 | +13.7% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $1.40 | $1.73 | +23.6% | ✓ BEAT |
Q3 2023 | Aug 15, 2023 | $1.48 | $1.55 | +4.7% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $1.49 | $1.74 | +16.8% | ✓ BEAT |
Q1 2023 | Feb 2, 2023 | $1.13 | $1.32 | +16.8% | ✓ BEAT |
Q4 2022 | Nov 4, 2022 | $0.96 | $1.20 | +25.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $1.17 | $1.05 | -10.3% | ✗ MISS |
Q2 2022 | May 5, 2022 | $1.54 | $1.45 | -5.8% | ✗ MISS |
Q1 2022 | Feb 3, 2022 | $1.23 | $1.27 | +3.3% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $1.32 | $1.29 | -2.3% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $1.18 | $0.77 | -34.7% | ✗ MISS |
Latest News
Barclays Initiates Coverage On Cardinal Health with Overweight Rating, Announces Price Target of $243
📈 PositiveWells Fargo Maintains Overweight on Cardinal Health, Raises Price Target to $221
📈 PositiveMizuho Maintains Outperform on Cardinal Health, Raises Price Target to $210
📈 PositiveTD Cowen Maintains Buy on Cardinal Health, Raises Price Target to $225
📈 PositiveCitigroup Maintains Neutral on Cardinal Health, Raises Price Target to $190
➖ NeutralUBS Maintains Buy on Cardinal Health, Raises Price Target to $220
📈 PositiveEvercore ISI Group Maintains Outperform on Cardinal Health, Raises Price Target to $220
📈 PositiveCardinal Health surges as it raises FY 2026 EPS guidance
📈 PositiveCardinal Health shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance above estimates.
📈 PositiveCardinal Health Raises FY2026 Adj EPS Guidance from $9.30-$9.50 to $9.65-$9.85 vs $9.43 Est
📈 PositiveCardinal Health Q1 Adj. EPS $2.55 Beats $2.18 Estimate, Sales $64.009B Beat $59.197B Estimate
📈 PositiveCardinal Health Plans To Establish Distribution Center In Indianapolis, Indiana
📈 PositiveU.S. Health Secretary Kennedy On Pharmacy Benefit Managers, Says In Talks With Industry, Pharma Cos; Have Committed To Some Protocol For Transparency; MFN Talks Would Include Direct-To-Consumer Marketing; Cannot Give Timing On Mifepristone Review
➖ NeutralCardinal Health drops after Q4 results; announces $1.9B acquisition
➖ NeutralFrequently Asked Questions about CAH
What is CAH's current stock price?
What is the analyst price target for CAH?
What sector is Cardinal Health, Inc. in?
What is CAH's market cap?
Does CAH pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CAH for comparison